
Jacob Bell
Senior Reporter | @realjacobbellJacob graduated from the University of Maryland with degrees in journalism and biology. He's previously reported on M&A at TheDeal, politics at McClatchy DC and education research at Education Week. His main interests include RuPaul's Drag Race, anything from the McDonalds menu and strong shoe game. He has loud opinions about avocado toast and Vine ending.
1421 articles by Jacob Bell
-
J&J, Legend’s cancer cell therapy has early success in key clinical trial
Jan. 27, 2023 -
Sales of J&J, Legend cell therapy plateau amid production challenges
Jan. 25, 2023 -
FDA to seek outside advice on Biogen’s ALS drug
Jan. 24, 2023 -
Why Wall Street shrugged at Lilly’s Alzheimer’s setback
Jan. 20, 2023 -
3 biotech executives on the year ahead: deals, drug pricing and the down market
Jan. 19, 2023 -
JPM23: Takeda tests Bristol Myers, Prime weighs spinoffs and Sanofi faces down a competitor
Jan. 11, 2023 -
JPM23: Califf on accelerated approvals, biotech startups’ looming cliff and an explanation from Editas
Jan. 10, 2023 -
JPM23: Vaccine developers as dealmakers, Gilead’s trial tea leaves and building platform companies
Jan. 10, 2023 -
FDA approves Alzheimer’s drug from Eisai, Biogen in closely watched decision
Jan. 6, 2023 -
Roivant reveals positive data for IBD drug, intensifying rivalry with Prometheus
Jan. 4, 2023 -
Gilead buys Tmunity, cozying up to a CAR-T pioneer
Dec. 20, 2022 -
Madrigal shares triple on positive NASH study results
Dec. 19, 2022 -
European regulators back hemophilia gene therapy
Dec. 16, 2022 -
For ALS patients, doctors, a new medicine reignites concerns about healthcare access
Dec. 15, 2022 -
Clovis files for bankruptcy
Dec. 12, 2022 -
Gilead buys into multiple myeloma cell therapy with Arcellx deal
Dec. 9, 2022 -
Vertex invests in a rare disease drug and its developer
Dec. 8, 2022 -
Prometheus shares soar on new data for inflammation drug
Dec. 7, 2022 -
Pfizer, Roivant set up new company around inflammation drug
Dec. 1, 2022 -
What to make of Eisai and Biogen’s Alzheimer’s drug results
Nov. 29, 2022 -
Axsome says drug eased Alzheimer’s symptom in positive study
Nov. 28, 2022 -
Narcan developer to be acquired by Indivior
Nov. 14, 2022 -
FDA declines to review Brainstorm’s ALS therapy
Nov. 11, 2022 -
Centerview grows role as go-to adviser for biopharma dealmaking
Nov. 8, 2022 -
Galapagos to cut 200 jobs amid research revamp
Nov. 4, 2022